Pfiz­er re­leas­es he­mo­phil­ia B PhI­II da­ta in chal­lenge to CSL's Hem­genix

Pfiz­er’s he­mo­phil­ia B gene ther­a­py showed strong re­sults in a Phase III tri­al, sharply re­duc­ing the rate of bleed­ing in pa­tients and dras­ti­cal­ly cut­ting their re­liance on the cost­ly in­jec­tions that are the cur­rent stan­dard of care.

The com­pa­ny said it plans to dis­cuss the da­ta with reg­u­la­tors ear­ly next year, and if the FDA does even­tu­al­ly ap­prove the treat­ment, it could present a chal­lenge to CSL Behring’s gene ther­a­py Hem­genix, which was ap­proved for use on Nov. 22.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER